Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.

Since 2001, chronic myelomonocytic leukemia (CMML) is classified by the WHO as myeloproliferative/myelodysplastic neoplasm. Herein we tried to better describe CMML patients with regard to hematological characteristics and prognosis using data of the Duesseldorf registry. We created 6 CMML subgroups, by dividing dysplastic and proliferative CMML at the cut-off of white blood cell count of 13,000/μL and splitting these two groups into 3 subgroups: CMML 0 with <5% blasts (n=101), CMML I with 5-9% blasts (n=204) and CMML II with 10-19% blasts (n=81). For comparison we included patients with RCMD, RAEB I and II. The newly created CMML 0 group had better prognosis than CMML I and II, median survival times were 31 months (ms), 19ms and 13ms, respectively (p<0.001). Median survival times between the corresponding dysplastic and proliferative subgroups 0 and 1 differed significantly: CMML 0 dysplastic 48ms and CMML 0 proliferative 17ms (p=0.03), CMML I dysplastic 29ms and CMML I proliferative 15ms (p=0.008), CMML II dysplastic 17ms and CMML II proliferative 10ms (p=0.09). Outcome of CMML patients worsens with increasing medullary blasts and when presenting as proliferative type. Therefore it is justified to separate CMML with <5% medullary blasts.

[1]  Martin Dugas,et al.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Gralnick,et al.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.

[3]  P. Morel,et al.  Cytogenetics of myelodysplastic syndromes. , 1996, Seminars in hematology.

[4]  J. Bueno,et al.  Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. , 2002, Leukemia research.

[5]  S. Ogawa,et al.  SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). , 2012, Blood.

[6]  U. Germing,et al.  Problems in the classification of CMML--dysplastic versus proliferative type. , 1998, Leukemia research.

[7]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[8]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[9]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[10]  D. Birnbaum,et al.  TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia , 2009, Haematologica.

[11]  U. Germing,et al.  Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. , 2006, Haematologica.

[12]  L. Arenillas,et al.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.

[13]  U. Germing,et al.  No increase in age-specific incidence of myelodysplastic syndromes. , 2004, Haematologica.

[14]  G. Mufti,et al.  Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival , 1988, British journal of haematology.

[15]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[16]  J. Cigudosa,et al.  Cytogenetic risk stratification in chronic myelomonocytic leukemia , 2011, Haematologica.

[17]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[18]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.